Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban for Leaflet Thickening After TAVI
NCT04171726Phase 3Unknown
- Sponsor
- Erasmus MC
- Start
- Aug 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of edoxaban in bioprosthetic valve thrombosis (BPVT), sponsored by Erasmus MC. Primary endpoint: Incidence of aortic valve leaflet thickening at 3 months. Status: unknown.
02
Drugs
edoxaban
03
Conditions
bioprosthetic valve thrombosis (BPVT)
Beyond the preview
Go deeper on NCT04171726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171726.